Intercept Soars on Report of Potential Acquisition Suitors

Updated on

Intercept Pharmaceuticals Inc., which is developing a liver disease drug that would be its first product, rose 28 percent in its biggest gain in two years after a report that the company is receiving interest from potential acquirers.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.